網頁

醫藥 - SAPA career talk 2/8 World Medical Innovation Forum 5/2-4, 2022




You are in for a treat!  Yes, instead of a “fireside chat”, we will have a “piano-side chat”  with the same concept and relaxed atmosphere but with a tune-twist in it, to warm up your heart and soul, and to light your paths forward. 

We are delighted to invite back the keynote speaker Margaret Wacyk from last year’s SAPA Career Development Workshop Mater Class, and this time joined by one of her students who is also a truly seasoned executive and an exemplary leader in the pharma industry  Dr. Andreas Jessel to join this engaged conversation.  We will learn from both of them the joy and essence of integrating art and leadership to enhance our capabilities and communication styles, and we invite you to be part of this unforgettable conversation.

Time: Tuesday, February 8, 2022, 8 – 9:30 pm.


REGISTER HERE


Andreas Jessel, MD

VP, Global Project Head
Sanofi

Dr. Jessel is the Global Project Head at Sanofi.  A physician-scientist with broad experience across the full pharmaceutical R&D value chain with focus on project leadership in multiple therapeutic areas, including immunology, cardio-vascular, and oncology.

Dr. Jessel has advanced analytical skills, strategic thinking capabilities and strong team leadership competencies. He is independent, engaged, with a positive and goal-directed work style.

Margaret Wacyk

Classical Pianist, Author, Educator,
and Founder of TheGrandManner.com


Hailed by the American Music Guide for her “versatility in many styles that emphasize chameleon-like transformations” Margaret is a trailblazer who is breathing new life into the art of piano playing.

Margaret is a concert pianist trained in the 19th century tradition of Golden Tone. Additionally, she is the author of two books, a composer and recording artist. Her second recording, Piano Works was chosen as Gramophone Magazine’s Best New Releases from North America.



Sincerely,

SAPA Executive Council





Linkedin

© 2022 SAPAweb.org All Rights Reserved.

You are currently subscribed to receive email news and promotions from SAPAweb.org.

To ensure continued delivery of this e-mail, please add sapa-announce@sapaweb.org to your e-mail address book.

How to add sapa-announce@sapaweb.org to your safe sender list in Gmail:
1. Go to settings.
2. Click on the “Filters and Blocked Addresses” tab.
3. Click on “Create a new filter”.
4. Enter sapa-announce@sapaweb.org in the “Filter from” area.
5. Click on “Create filter”.
6. Check the box before “Never send it to Spam”.
7. Click on “Create filter”.

If you would like to unsubscribe from SAPA, please send an email to sapa-announce@sapaweb.org with the subject “UNSUBSCRIBE”

Sino-American Pharmaceutical Professionals Association
P.O. Box 3228, 213 Carnegie Center, Princeton, NJ 08540


Public Anyone on or off Facebook
【Career Development Series】How to Interview Like a Pro?

✨ How to make your application stand out?
❓ What are the top interview mistakes?
👉 “You are hired!” learn from the perspective of a hiring manager
Welcome to the first workshop of the Career Development Series! This workshop will focus on practical tips to help you stand out in your interviews. Join the workshop to learn key skills and career strategies to improve future possibilities!

▶️ 𝗧𝗶𝗺𝗲: January 23 (Sun), 2 pm to 4:00 pm EST
▶️ 𝗣𝗹𝗮𝗰𝗲: Virtual event
▶️ 𝗥𝗦𝗩𝗣: https://forms.gle/35PWZniogrjaMLbX6

*** 本活動將會以英文進行 ***
✨ 想知道如何才能從眾多履歷中脫穎而出嗎?
❓ 想知道面試中大家經常犯哪些錯誤呢?
👉 「你被錄取了!」想知道主管在面試時,都會看哪些眉眉角角呢?

想得到理想中的工作嗎?絕不要錯過 Career Development Series 的第一場講座 – How to Interview Like a Pro? 我們邀請到曾任職於以Co-op著稱的東北大學職涯顧問及三位藥廠主管,他們將分享如何在面試中脫穎而出的技巧,以及面試中的常見誤區,讓你求職過程更加如虎添翼!

▶️ 時間: 1/23 (日), 東岸時間下午 2-4點
▶️ 地點: 線上活動
▶️ 報名: https://forms.gle/35PWZniogrjaMLbX6

▶️ SPEAKERS
✽ Nancy Waggner. Former Graduate Coop & Internship Coordinator, Department of Pharmaceutical Sciences, Northeastern University
✽ Yvonne Meng, PhD. Principal Scientist, Biologics Discovery, Janssen Biotherapeutics (JBIO) at Johnson & Johnson
✽ Ho-Chou Tu, PhD. Associate Director, Alnylam Pharmaceuticals
✽ Shian-Huey Chiang, PhD. Director, Head of Emerging Science Biology, Target Sciences, ES&I, Pfizer Inc.

▶️ MODERATOR
✽ Yvonne Meng, PhD. Principal Scientist, Biologics Discovery, Janssen Biotherapeutics (JBIO) at Johnson & Johnson (https://www.linkedin.com/in/hwyvonnemeng/)

▶️ Event agenda:
2:05 pm - 2:30 pm Speech by Ms. Nancy Waggner
2:30 pm - 3:10 pm Panel discussion
3:10 pm - 3:25 pm Q & A
3:25 pm - 3:45 pm Networking

▶️ Next Career Development Series Event:
1/25 (Tue) 8:30 pm - 10:00 pm Professional Career – Where Do We Go From Here? (Hosted by NEACP)

▶️ Co-Host Organizations:
Education Division, TECO in Boston
Harvard GSAS Taiwan Student Association (HTSA)
New England Association of Chinese Professionals (NEACP)
The Federation of Taiwanese Students Association of New England (FTSANE)

▶️ Guest Bio
NANCY WAGGNER
Nancy has over 25 years of experience helping students and alumni prepare for success in their chosen fields or discovering new fields of interest if the need arises. Nancy is recently retired, after working at Northeastern University for nearly twenty years, as well as Brandeis University and Roger Williams School of Law. In her most recent position at Northeastern’s Department of Pharmaceutical Sciences, she developed and taught a course to prepare students, most of whom were international, for looking for and finding jobs. She enjoys helping people find their talents and learning how to help potential employers know what those talents are.
Linkedin: https://www.linkedin.com/in/nancy-waggner-125922a/

HO-CHOU TU
Dr. Ho-Chou Tu is an Associate Director at Alnylam Pharmaceuticals, where she is a research lead in multiple early-stage pre-clinical programs using RNAi-based therapies. These include interdisciplinary approaches combining clinical, in vitro & in vivo models, bioinformatics & data analysis to address important topics in the drug discovery process, including exploratory biomarker identification & validation.
Ho-Chou holds a B.S. in Zoology from National Taiwan University and a Ph.D. in Cell and Molecular Biology from Washington University. Previously, Ho-Chou worked as a Research Fellow at the Memorial Sloan-Kettering Cancer Center (2010-2011) and Boston Children’s Hospital (2011-2015).
Linkedin: https://www.linkedin.com/in/ho-chou-tu/

SHIAN-HUEY CHIANG
Dr. Shian-Huey Chiang, is currently Director and Head of Emerging Science Biology, Target Sciences, in Emerging Science & Innovation (ES&I) organization in Pfizer, Boston. Her research focuses on target validation in inflammatory diseases, rare diseases, cancers, metabolic syndrome, and fibrosis.
Shian-Huey received her bachelor’s degree from the Department of Agriculture Chemistry, National Taiwan University in 1991 and a master’s degree in Biochemistry from National Yang-Ming University in 1994. Shian-Huey received her PhD in the Cellular and Molecular Biology Program at the University of Michigan, Ann Arbor in 2001, where she studied the insulin signaling pathway. During her tenure at the University of Michigan, she published numerous first-author papers in Nature, Cell, and Nature Medicine. After that, she joined GlaxoSmithKline as an investigator in North Carolina (2011-2015) and joined Pfizer as a Principal Scientist and Senior Principal Scientist at Centers for Therapeutic Innovation (CTI) in Boston (2015~2019).
Linkedin: https://www.linkedin.com/in/shianhueychiang/

YVONNE MENG
Dr. Yvonne Meng is currently a Principal Scientist of Janssen Biotherapeutics (JBIO) at Johnson & Johnson in Boston. Her research interests focus on therapeutic biologics discovery and protein engineering.
Prior to Johnson & Johnson, Yvonne received her BSc in Life Sciences from the National University of Kaohsiung in 2006, and her PhD in Biomedical and Biological Sciences from Cornell University in 2013. After graduation, she joined the industry as a Postdoctoral Research Fellow at Pfizer (2014-2015), Staff Scientist at Takeda (2015-2016), Senior Scientist at Merck (2016-2020), and a Senior Scientist Group Lead at Entrada Therapeutics (2020).
Linkedin: https://www.linkedin.com/in/hwyvonnemeng/

▶️ Co-Host Organizations:
◆ Education Division, TECO in Boston
◆ Harvard GSAS Taiwan Student Association (HTSA)
◆ New England Association of Chinese Professionals (NEACP)
◆ The Federation of Taiwanese Students Association of New England (FTSANE) 
See less

Thank you very much for attending the first 2022 BTBA Academic Seminar! We want to thank the speakers -- Drs. Ya-Yun Cheng and Meng-Ju Wu -- for sharing their research with us! Special thanks to the moderator, Dr. Fan-Yun Lan, for hosting and facilitating the panel discussion.

If you miss the workshop, check out
������ https://youtu.be/LInxDLriykc
Save the dates!!

Career Development Series

PART I: How to Interview Like a Pro?

▶️ Time January 23 (Sun), 2:00 pm to 4:00 pm EST
▶️ Host Organization: BTBA; HTSA
▶️ RSVP: https://forms.gle/DutEGitzx6xXst5H9


PART II: Professional Career: Where Do We Go From Here?

▶️ Time January 25 (Tue), 8:30 pm to 10:00 pm EST
▶️ Host Organization: NEACP
▶️ RSVP: https://forms.gle/Dr8ARV9GGagZwwWT6


BTBA January Monthly Meeting

Link:  https://harvard.zoom.us/j/95162985672?pwd=SmpHRS9VSHNRVzNha2hBanVieWdzUT09


World Medical Innovation Forum | May 2–4, 2022

 

 

Happy Innovative Holidays!

 

 

Have a safe and happy holiday season! The World Medical Innovation Forum is coming in the New Year. Gene and cell therapy – medicine’s game changer, is the focus.

 

MAY 2–4, 2022

Join us for three unrivaled days in May.

Early bird rates expire January 15.

 

 

 

 

The Forum team will continue to monitor COVID-19 and event safety protocols. Updates regarding the format of our event will be shared later this winter.

 

 

 

Confirmed Speakers

 

Global leaders will share their insights on GCT, biotech and the future of care.

 

Albert Bourla, PhD

CEO, Pfizer

 

Robert Bradway

CEO, Amgen

 

Marc Casper

CEO, Thermo Fisher Scientific

 

Sekar Kathiresan, MD

CEO, Verve Therapeutics

 

Anne Klibanski, MD

CEO, Mass General Brigham

Stephen Knight, MD

President & Managing Partner, F-Prime Capital

 

Peter Marks, MD, PhD

Director, Center for Biologics Evaluation and Research, FDA

 

Andrew Plump, MD, PhD

President, R&D, Takeda

 

John Reed, MD, PhD

EVP, Global Head of R&D, Sanofi

 

Ned Sharpless, MD

Director, National Cancer Institute

 

 

 

Selected Topics

 

Featured topics include:

 

Capital Formation | Shaping Innovation

 

Cell Therapy | CAR-T to Stem Cells

 

Chronic Neuroinflammation

 

Clinical GCT Trial Design | Risk vs Hype

 

Covid-Driven mRNA Opportunities

 

Creating the Enduring Framework to Ensure GCT Safety Mitigating

 

Disrupting Surgical Interventions | Robotic Surgery

Expert Briefings on the Components of GCT – Leading Clinicians Explain the Potential and Challenges

 

GCT Development Centers | Academia’s Unique Contribution

 

GCT Patient Perspectives 

 

GCT’s Historic Context – How Much Will it Change Medicine

 

Gene and Cell Therapy | The World Speaks

 

The Global Biotech Epicenter | New England Now and in 2030

 

Manufacturing | Process Control – It's Harder Than You Think

 

 

World Medical Innovation Forum

感謝您這一年對BTBA的支持,讓我們在2021年持續成長。12/11() BTBA將有兩場活動:Academia Panel - The Journey from Postdoc to PI 以及呂家鋒律師的特別演講曲速行動的背後 - COVID19醫藥品全球開發供應的考量。歡迎各位報名參加!演講內容及報名資訊附於下方。

 

祝福各位佳節愉快,新的一年也要請您們多多指教!明年度BTBA的活動將持續公告於我們的社群媒體,期待見到各位!

 

曲速行動的背後 - COVID19醫藥品全球開發供應的考量 (實體活動)

Greenberg Traurig資深合夥律師呂家鋒將分享COVID-19疫苗和藥品的開發和商業化過程的考量。呂律師將提供其第一線參與曲速行動的觀察,解釋美國決定採取曲速行動 (Operation warp speed) 的來由,以及其代表廠商參與跟國家及超國家組織的談判中如何建構產品的供應和採購的過程。

 

講者:呂家鋒 (Chia-Feng Lu) 律師 (Greenberg Traurig國際法律事務所 資深合夥人)

主持人: 杜荷洲 (Ho-Chou Tu) 博士 (Associate Director, Alnylam Pharmaceuticals)

報名表: https://forms.gle/dfzuteXCV5ZCnyCK8 (報名截止於 129日晚上11點,或額滿為止)

時間: 12/11 (Sat) 2:00PM - 4:00PM (EST)

地點: Mount Auburn Room, 2F, Harvard Smith Campus Center (1350 Massachusetts Ave, Cambridge, MA 02138)

 


2021 BTBA Dec Workshop The Journey from Postdoc to PI (線上活動)

 

四位分別在美國及台灣學術界擔任PI的優秀學者齊聚一堂。將在短短一個半小時中,不藏私地與大家分享當上PI前後的心境轉折、需要克服的困難等等,絕對滿足你對於美國及台灣學術界的好奇心,還有可能會聽到一些網路上搜尋不到的學術界小秘密喔!如果你正佇足於學術界與業界的交叉路口,別再猶豫了!快來報名參加BTBA 12月的線上學術專題論壇:從博後變身為PI的心路歷程大分享。

 

時間: 1211 () 上午十點 (東岸時間); 晚上十一點 (台灣時間)

地點: Online event via Zoom

報名: https://reurl.cc/RbGR5D 

講者

  • 鄭佳瑋: Assistant Professor at Columbia University Irving Medical Center 
  • 王志豪: 助理教授, 中國醫藥大學醫學院-生物醫學研究所 
  • 蔡佩珊: Assistant Investigator, Lilly Diabetes Center of Excellence at the Indiana Biosciences Research Institute
  • 郭瑋庭: 助理教授, 台灣大學醫學院-口腔生物科學研究所 

主持人:

  • 程吉安, 博士後研究人員, 布萊根婦女醫院及Wyss Institute 
  • 吳孟儒, 博士後研究人員, 麻省總醫院癌症中心 

--

BTBA 敬邀



✨【2021 BTBA Dec Workshop】The Journey from Postdoc to PI ✨

(The workshop will be conducted in Mandarin)

🎓 Are you interested in a career in academia but still have doubts or questions? Come and hear from our group of panelists, who will share their first-hand experiences of what an academic life looks like when transitioning from postdoc to PI!

▶️ 𝗧𝗶𝗺𝗲: Dec 11 (Sat), 10-11:30 am (EST) 11-12:30 pm (Taiwan Time)
▶️ 𝗣𝗹𝗮𝗰𝗲: Online event via Zoom
▶️ 𝗥𝗦𝗩𝗣: https://reurl.cc/RbGR5D
▶️ 𝗦𝗽𝗲𝗮𝗸𝗲𝗿:
❖ Chia-Wei Cheng, Assistant Professor at Columbia University Irving Medical Center
❖ Chih-Hao Wang, Assistant Professor at Graduate Institute of Biomedical Sciences, China Medical University
❖ Erica Cai, Assistant Investigator in the Lilly Diabetes Center of Excellence at the Indiana Biosciences Research Institute
❖ Wei-Ting Kuo, Assistant Professor at Graduate Institute of Oral Biology, College of Medicine, National Taiwan University
▶️ 𝗠𝗼𝗱𝗲𝗿𝗮𝘁𝗼𝗿:
❖ Annie Cheng, Postdoctoral research fellow, Brigham and Women’s Hospital, Wyss Institute
❖ Meng-Ju Wu, Postdoctoral research fellow, Massachusetts General Hospital Cancer Center
-

🎧 聽完 #生技來一刻「學界PI迷思大破解」後覺得意猶未盡嗎?
❓ 想更深入了解自己究竟適不適合學術界嗎?
🧐 想聽聽台灣與美國學術界的差異與秘辛嗎?
🔬 究竟擔任PI的一天是什麼樣子呢?

是不是對於PI這個職位還有很多想問的問題呢?我們都聽到你的心聲了!BTBA一口氣邀請到四位,分別在美國及台灣學術界擔任PI的優秀學者齊聚一堂。將在短短一個半小時中,不藏私地與大家分享當上PI前後的心境轉折、需要克服的困難等等,絕對滿足你對於美國及台灣學術界的好奇心,還有可能會聽到一些網路上搜尋不到的學術界小秘密喔!
如果你正佇足於學術界與業界的交叉路口,別再猶豫了!快來報名參加BTBA 12月的線上學術專題論壇:從博後變身為PI的心路歷程大分享。

▶️ 時間: 12月11日 (日) 上午十點 (東岸時間); 晚上十一點 (台灣時間)
▶️ 地點: Online event via Zoom

▶️ 講者:
❖ 鄭佳瑋: Assistant Professor at Columbia University Irving Medical Center
❖ 王志豪: 助理教授, 中國醫藥大學醫學院-生物醫學研究所
❖ 蔡佩珊: Assistant Investigator, Lilly Diabetes Center of Excellence at the Indiana Biosciences Research Institute
❖ 郭瑋庭: 助理教授, 台灣大學醫學院-口腔生物科學研究所

▶️ 主持人:
❖ 程吉安, 博士後研究人員, 布萊根婦女醫院及Wyss Institute
❖ 吳孟儒, 博士後研究人員, 麻省總醫院癌症中心
-
【Speaker】
CHIA-WEI CHENG 鄭佳瑋
Dr. Cheng conducted her doctoral research in Dr. Valter D. Longo's laboratory at the University of Southern California (USC). She completed her postdoctoral training in Dr. Omer H. Yilmaz's laboratory at Koch Institute at Massachusetts Institute of Technology (MIT). Dr. Cheng was a fellow of Helen Hay Whitney Foundation (HHWF) and is an awardee of the NIH Pathway to Independence Award (K99), with Dr. David M. Sabatini's co-mentorship. Earlier this year, Dr. Cheng joined Columbia University Irving Medical Center (CUIMC) as an assistant professor in the Department of Genetics and Development (G&D) and Columbia Stem Cell Initiative (CSCI). Her Lab studies the molecular machinery that translates nutritional cues into cell-fate determinants. Her goal is to decipher the nutrigenomic underpinning of stem cell identity in the hopes of inspiring new therapeutic strategies.
-
CHIH-HAO WANG 王志豪
Dr. Wang received his Ph.D. degree in Taiwan and finished his postdoctoral training at Joslin Diabetes Center, Harvard Medical School, Boston, USA. He is currently an assistant professor in the Graduate Institute of Biomedical Sciences at China Medical University, Taichung, Taiwan. His research focuses on using pharmacological and genetic approaches to activate brown fat and/or white fat browning and investigating the underlying mechanisms. His ultimate research goal is to apply those basic scientific findings to regulate whole-body energy metabolism for the treatment of obesity, diabetes, and metabolic disorders.
-
ERICA CAI 蔡佩珊
Erica Cai, PhD, obtained her bachelor’s degree in medical technology from Taipei Medical University and her master’s degree in biochemistry and molecular biology from National Taiwan University. She was trained by Dr. Minna Woo and received her Ph.D. in medical science from the University of Toronto, Canada.
Cai was an instructor in medicine at the Harvard Medical School. She worked in the laboratory of Dr. Peng Yi and the CRISPR screen core facility at the Joslin Diabetes Center. Her research projects used a multidisciplinary approach to investigate beta-cell physiology, including cell regeneration, cell function, stress response, and autoimmune protection. Dr. Cai joined the Lilly Diabetes Center of Excellence within the IBRI Diabetes Center in April 2021. She also is a member of the Indiana University Center for Diabetes and Metabolic Diseases. Cai’s current research focuses on beta-cell protection and diabetes prevention. Her ultimate research goal is to better understand diseases and help improve patients' quality of life.
-
WEI-TING KUO 郭瑋庭
Dr. Kuo is an assistant professor in the Graduate Institute of Oral Biology, College of Medicine, National Taiwan University. His laboratory investigates the physiological and pathological mechanisms of tight junction (TJ) protein regulation in epithelial organisms and mucosal homeostasis. Their research interests focus on the role of TJ proteins in mucosal repair and cancer pathogenesis.
【Moderator】
CHI-AN (ANNIE) CHENG 程吉安
Dr. Annie Cheng obtained her bachelor’s and master’s degrees in chemistry from National Taiwan University. She was trained by Dr. Jeffrey Zink and received her Ph.D. in bioengineering from the University of California, Los Angeles (UCLA). During her Ph.D. training, she was awarded the UCLA Dissertation Year Fellowship. Annie is now a postdoctoral research fellow at Brigham and Women’s Hospital of Harvard Medical School and Wyss Institute. Since the COVID-19 pandemic, her research has focused on COVID-19 serology studies such as COVID-19 vaccine evaluation.
-
MENG-JU WU 吳孟儒
Dr. ​​Meng-Ju Wu obtained his bachelor’s and master’s degrees from National Yang-Ming University. He conducted his doctoral research in Dr. Alice Chang’s laboratory at Purdue University. Meng-Ju is now a postdoctoral fellow of the American Cancer Society (ACS) with Dr. Nabeel Bardeesy and Dr. Robert Manguso's co-mentorship at Massachusetts General Hospital (MGH). His research focuses on how tumor metabolism affects tumorigenesis and the tumor microenvironment.


美中醫學交流協會ACMES邀請您參加本週六的學術講座
2021年12月11日, 週六下午1-3點
Zoom ID: 988 5791 1027, password 062663
1-2PM,嗎啡類藥物在慢性疼痛的應用,茅建人醫師,哈佛冠名教授,麻省總院疼痛科主任
2-3PM,新冠疫苗-效力和應用,劉西平博士,加州南特凱捷健公司藥理及免疫學主任
 
主持人:林旭醫師,MD,哈佛醫學院副教授
               胡克勤醫師,MD,加州大學爾灣分校教授
 
講員介紹:
 
茅建人醫師(MD,PHD)是哈佛醫學院麻醉研究Richard J. Kitz 冠名教授,他獲得了麻醉學和疼痛醫學委員會的認證,自 1999 年以來一直在麻省總醫院 (MGH) 執業。茅博士是麻省總醫院的疼痛醫學部主任,作為首席研究員曾獲得十項 NIH R01 資助、一項 NIH P20 計劃項目資助、一項 NIH U24 資助,並且還是十多項 NIH R01 和 R21 資助的共同研究者。茅博士曾擔任多個專業期刊的執行編輯或副主編,四十餘種專業期刊的審稿人,以及美國國立衛生研究院和加拿大研究委員會等的資助申請審核人等。茅博士是1997年美國疼痛學會傑出早期職業獎的獲得者和 2012 年美國區域麻醉和疼痛醫學學會John J. Bonica獎的獲得者,他撰寫或合著了超過 200 篇出版物、100 多篇摘要,並作為唯一編輯出版了四本書。
 
劉西平博士(PHD)畢業於上海第一醫科大學(復旦大學)藥學院,在中南大學湘雅醫學院獲分子生物學博士,美國南加州大學和國家癌症研究中心博士後。他曾擔任新基生物製藥公司免疫學部主管和高級科學家。目前在加州 美國南特凱捷健生物技術有限公司擔任生物藥理和免疫部主任。劉西平博士曾參加過病毒以及腫瘤疫苗的研究和開發,對疫苗的特性有獨到認識。 2021年,在美國華裔教授學者協會和南加州華人科技協會年會上就SARS-CoV-2和疫苗進行了多次科普講座。





謝謝你們有表達加入2021-2022 BTBA年會籌備小組的意願,很誠摯邀請各位的加入,為明年年添加更多的能量與多元的專才!我們歡迎各個職涯階段的專業人士、學生的加入,讓BTBA可以提供不同階段的生醫人士成長學習的空間。

 

第一次的籌備會議將於11/21 () 下午3:40-4:40進行。屆時將會介紹各大組的負責人給大家認識,並介紹各大組今年度的工作項目與目標。我們也將腦力激盪明年度年會安排。期待大家的加入!若這次不方便參加,12月份也會有籌備會議,到時候會再跟大家告知細節。


另外,11/21 () 下午2:00-3:40有介紹 Computational biology 的職涯講座,歡迎各位參與、分享給親朋好友喔!!

各大組工作內容:

  • 學術組/業界組:規劃月會活動、年會內容、講座安排
  • 募款組:代表BTBA向各大企業投遞募款申請書
  • 宣傳組:經營BTBA社群媒體 (Facebook, Twitter, Linkedin)、宣傳活動
  • 新聞組/Content editor: 撰寫活動記錄、編輯、校閱、翻譯BTBA的對外正式文件
  • 生技來一刻 Podcast 組:策劃節目內容、邀請與訪談講者、編輯後製
  • IT組:更新與維護官方網站、售票
  • 財務組
  • 稅務組

期待11/21能見到大家!如果有什麼建議或是想法,都歡迎聯絡祐湉 (yutienhsu@g.harvard.edu; Messenger: Yu-Tien Hsu) 或致宏 (chchou23@gmail.com; Messenger: Chih-Hung Chou)

2021 SAPA-NE and SAPA-CT Joint Annual Conference

Lynk Pharmaceuticals announced the completion of Series B financing of $50 million 

English

Lynk Pharmaceuticals Co., Ltd.

2021-08-27 08:00  1848


 Lynk Pharmaceuticals announced the completion of Series B financing of $50 million - PR Newswire APAC (prnasia.com)

HANGZHOU, ChinaAug. 27, 2021 /PRNewswire/ -- Lynk Pharmaceuticals CO., LTD (hereinafter referred to as "Lynk Pharmaceuticals"), an innovative pharmaceutical R&D company, today announced that it has successfully completed Series B financing of $50 million, with Lilly Asia Ventures (LAV) as lead investor, New Alliance Capital and Hangzhou HEDA Biological Medicine Venture Capital Partnership (L.L.P.) as co-investors, and its original shareholders Legend Capital and Med-Fine Capital as participating investors. The proceeds from this round of financing will mainly be used to conduct Phase I and II clinical trials for multiple programs in the R&D pipeline of Lynk Pharmaceuticals. In addition, the funding will be used to expand international business, strengthen international collaborations with leading companies and support preclinical development of new projects. CEC Capital acted as the exclusive financial advisor to Lynk Pharmaceuticals in this transaction.

Founded in 2018, Lynk Pharmaceuticals is a globally leading innovative drug R&D company. Based on the team's world-leading experience in medicinal chemistry and small molecule clinical development, it is dedicated to the development of global FIC/BIC small molecule drugs for autoimmune diseases, inflammation and cancers. In three and a half years since its establishment, Lynk has obtained IND approvals for three original products in China and the United States, launched global clinical development efforts, and completed the ex-Chinese rights out-license of LNK01001 to a US company and the in-license of the first-in-class RAS program from Japan's Kobe University and RIKEN, both in 2020.

Dr. Zhao-Kui (ZK) Wan, Chairman and CEO of Lynk Pharmaceuticals, said, "We are very much grateful for the recognition and support from the top investors in the industry. Since the establishment of Lynk Pharmaceuticals, we have been advancing our projects with efficient execution, and we have made significant progress in just three and a half years. This round of financing will lay a solid foundation for us to further develop our pipeline and continue to advance innovative therapies. Owing to the great efforts of many scientists and investigators, I believe that we will benefit patients with innovative therapies as soon as possible."

According to Dr. Ting Feng, Vice President of Lilly Asia Ventures (LAV), "We are deeply impressed by the efficient execution and global vision of Lynk Pharmaceuticals' management team. We are also very optimistic about the future huge market space and the unmet patient needs in the field of autoimmune disease and cancer. We are excited to partner with the Lynk team to accelerate its growth and look forward to more breakthroughs and successes in the future with our innovation capability."

Lei Cai, Managing Director at New Alliance Capital, commented"there have been huge unmet needs as well as great potential for small molecule drugs to treat autoimmune disease and cancer. Lynk's international vision and strong team execution have left a deep impression on us; we are very happy to have the opportunity to work with Lynk. New Alliance Capital will provide full support in all aspects of capitals and industry resources to support the company to become a global leader and bring more effective solutions to benefit patients across the world."


[This Thu] SAPA-NE 2021 Bimonthly Workshop

July 22, 2021, Thursday, 8:30 PM - 10:00 PM EDT

FREE ZOOM WEBINAR

 

Dear SAPA-NE Members and Friends,


The Sino-American Pharmaceutical Professionals Association–New England/Boston (SAPA-NE) is glad to announce that SAPA-NE 2021 Bimonthly Workshop, 
Recent Individual Tax Development in the US and China, will be held in 4 days. The workshop will be presented by EY China overseas investment, people advisory services. This event will be held virtually on Thursday, July 22, 2021 and will be delivered in Mandarin.

 

Please contact us at info@sapa-neweb.org if you have any membership or registration-related questions. 

 

Agenda Topics

 

·       US individual tax filing and disclosure requirements

·       Outlook for Biden’s proposed tax plans on impacts on individuals

·       US expatriation rules for US citizens and green card holders

·       China individual income tax reform and annual tax filing requirements

·       Individual tax planning considerations, such as US citizens and greencard holders working / investing in mainland China

·       Q&A 

July 22, 2021, Thursday, 8:30 PM - 10:00 PM EDT

FREE ZOOM WEBINAR

How to become a SAPA-NE Member?

Paid Membership Rate

Student & Postdoc (Annual): $15

Professionals (Annual): $30

Life-time: $300

Note: Paid membership will be effective immediately after purchase

 BIO Digital Taiwan Day

Accelerating Biotech innovation through global collaboration with healthcare, VC and though leaders

About this event

Taiwan Start-up Pitch

Chung-Chu Chen, CEO of Somnics

Ed Deng, Health2Sync

Panel 1 : Post-COVID Solution and Challenges in Healthcare

Salman Al-Sabah, Chairman of Surgery of Jaber Al-Ahmad Al-Sabah Hospital, Kuwait

Helen Chen, CMO of Hewbrew SeniorLife

Peter Lee, Medical Director, Amazon

Po-Shun Lee, CMO of PlateletBio

Panel 2 : Digital Transformation with Pharma

Tony Chan, Morgan, Lewis & Bockius, Partner and Leader, DC Corporate Group

Robert Lake, Managing Director, Runway Growth Capital

Kevin Lalande, Santé Ventures, Founding Managing Director & CIO

Sandeep M Menon, SVP and Head of Early Clinical Development, Pfizer Tony Chan, Partner, Morgan Lewis

𝐁𝐓𝐁𝐀 𝟐𝟎𝟐𝟏 𝐀𝐧𝐧𝐮𝐚𝐥 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦
𝐓𝐢𝐦𝐞
July 10 & 11 (Saturday and Sunday) 2021
12:50 pm to 6:30 pm EDT
𝐑𝐒𝐕𝐏
Eventbrite: ibit.ly/AZSJ
**Free event! Space is limited, REGISTER TODAY!**
[Webinar link and password will be sent to you on 7/10/2021 morning]
This online symposium will bring experts from academia and industry to share their experiences and knowledge on their research/responsibility, personal career development, and lessons learned for young scientists. This year, we are honored to have Dr. Herren Wu, Ph.D., the Senior Vice President of AstraZeneca, and Dr. Jeannie T. Lee, M.D., Ph.D., Professor of Genetics of Harvard Medical School.
𝐊𝐞𝐲𝐧𝐨𝐭𝐞 𝐒𝐩𝐞𝐚𝐤𝐞𝐫𝐬
𝑯𝒆𝒓𝒓𝒆𝒏 𝑾𝒖, 𝑷𝒉.𝑫. | 𝐒𝐞𝐧𝐢𝐨𝐫 𝐕𝐢𝐜𝐞 𝐏𝐫𝐞𝐬𝐢𝐝𝐞𝐧𝐭 𝐨𝐟 𝐀𝐬𝐭𝐫𝐚𝐙𝐞𝐧𝐞𝐜𝐚
𝑱𝒆𝒂𝒏𝒏𝒊𝒆 𝑻. 𝑳𝒆𝒆, 𝑴.𝑫., 𝑷𝒉.𝑫. | 𝐏𝐫𝐨𝐟𝐞𝐬𝐬𝐨𝐫 𝐨𝐟 𝐆𝐞𝐧𝐞𝐭𝐢𝐜𝐬 𝐨𝐟 𝐇𝐚𝐫𝐯𝐚𝐫𝐝 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐒𝐜𝐡𝐨𝐨𝐥
𝐀𝐛𝐨𝐮𝐭 𝐁𝐓𝐁𝐀
As a non-profit organization, we appreciate your consideration of giving a small gift to support BTBA! Your donation qualifies for tax-exemption and grants you guaranteed access to the 2021 BTBA Virtual Symposium meeting rooms.
*Keynote, academia, and industry sessions will be conducted in English*

XXX

Dear SAPA-NE members:

 

We are pleased to inform you the result of the SAPA-NE leadership election in 2021 as below:

President-Elect:
James Jianming Chao
 

Secretory general:
Kehao Zhao

The team is looking forward to working closely with you to build the community together!

Sincerely,
2021 Election Committee


The 22nd SAPA-NE Annual Conference

A New Era in Biotech and Life Science

 

Sat, Jan 23 | Free Zoom Webinar

9:00 AM – 6:00 PM EST

Seats are limited

Please register ASAP

Time: Sat, Jan 23rd, 9:00 AM – 6:00 PM EST

Language: English

Venue: Zoom Webinar, Spatial Chat (Virtual Networking, Job Hunting, Vendor Show)

Speakers & Presentation Topics

Agenda

Morning Sessions: 9:00AM-12:30PM

Noon Sessions: 12:30PM-2:00PM

Afternoon Sessions: 2:00PM-6:00PM

Speaker Bio

Dan Barouch, M.D., Ph.D.

Member, National Academy of Medicine; William Bosworth Castle Professor of Medicine, Harvard Medical School; Director, Center for Virology and Vaccine Research, BIDMC; Member, Ragon Institute of MGH, MIT, and Harvard

Eric Fischer, Ph.D. 

Eric Fischeris an Independent Investigator at Dana-Farber Cancer Institute, Associate Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School, and Co-Director of the DFCI Center for Protein Degradation. He and his lab have significantly contributed to our understanding of small molecule mediated protein degradation, and its widespread application in academia and industry. Dr. Fischer has co-founded Civetta Therapeutics, Jengu Therapeutics, and Neomorph and serves on the scientific advisory board for the Institute for Protein Innovation.

John Evans, MBA

John Evans joined Beam in 2017 as CEO, bringing significant experience as a company builder, dealmaker, and drug developer in the biotechnology industry. Mr. Evans is also a Venture Partner with ARCH Venture Partners.

Mr. Evans was previously an early employee and member of the leadership team at Agios Pharmaceuticals, most recently serving as Senior Vice President for Corporate Development and Portfolio Leadership. Prior to joining Agios, Mr. Evans worked at Infinity Pharmaceuticals, McKinsey & Company (Pharmaceuticals practice) and MedImmune.

Mr. Evans holds an M.B.A. in Healthcare Management from Wharton, a Masters in Biotechnology from the University of Pennsylvania, and a B.A. in English with distinction from Yale University.

Jamie Stokes, Ph.D.

Jamie received his PhD from University of Cambridge in 2014. Between 2014 and 2017 Jamie was a Roche Postdoctoral Research Fellow at Cambridge where he worked on a number of projects at the chemistry-biology interface including the design and synthesis of de-novo antibiotic-quorum sensing small molecule conjugates and the development of methodology to allow access to diverse collections of small molecule screening collections. Jamie has worked at Concept Life Sciences since 2017 on a number of different medicinal chemistry programs and has a special interest in new approaches to synthesis and antibody drug conjugates.

Zonghai Li, M.D., Ph.D.

Zonghai Li is the Chairman, Chief Executive Officer, Chief Scientific Officer and Founder of CARsgen Therapeutics. He is dedicated himself to develop curable treatment for the patients with cancer. One of his early career achievements is the identification of GE11, a peptide ligand of EGFR which has become one of the most widely used peptides in antitumor study now. He has a leading role in the research on CAR T cell therapy against solid tumors by publishing the first paper and advancing the first clinical trial of CAR T cell therapy against GPC3, Claudin18.2 and EGFR/EGFRvIII worldwide. He earned a M.D. and M.S. from Xiangya Medical School of Central South University and a Ph.D. from Fudan University.

Liang Schweizer, Ph.D.

Liang Schweizer is the co-founder, President and CEO of HiFiBiO Therapeutics, an emerging multinational biotherapeutics company. Previously, she was a co-founder and CSO for Harbour Biomed. Before launching her entrepreneurial career, Liang served as Head of Asian Cancer Research at Sanofi and Director of Leads Evaluation at Bristol-Myers Squibb Company. Under her leadership, her various teams made significant contributions to 4 marketed drugs and impacted over 20 clinical candidates. She is also a co-inventor of multiple immunomodulation drug candidates.

Dian Su, Ph.D.

Dian is a Senior Scientist in Drug Metabolism and Pharmacokinetics (DMPK) at Genentech. Her research focus has been on ADC/small molecule/peptide DMPK areas mainly in the pre-clinical stage. At DMPK, her primary focus lies in small molecule and peptide drug metabolism in discovery stage. In this role, her responsibilities include: 1) developing new generation assays for metabolite identification (Met ID) to improve the throughput and tackle challenges associated with drug metabolite ID; 2) exploring deep understanding of metabolite formation and biological impact, and establish structure−metabolism relationship (SMR) for drug metabolites. 

Yan Chen, Ph.D. Founder, President and CEO of Elpis Biopharmaceuticals

Yan brings more than 20 years of expertise in both mRNA display technology and biologic drug discovery in the oncology disease area. She was Biotherapeutics Discovery Head at Juno Therapeutics in Boston and Senior Vice President of Research at X-Body Biosciences which was acquired by Juno in 2015. Previously, she was an investigator and project leader in Oncology Biotherapeutics at Novartis Institutes for Biomedical Research. Earlier in her career, she was a scientist at Phylos and Adnexus playing instrumental roles in establishing the mRNA antibody and protein display technology platforms. Yan was a postdoctoral trainee in Immunology at Tufts Medical School and received her PhD in Tumor Immunology from National University of Singapore. She is the co-inventor of more than 20 antibody technologies and biologic therapeutics patents.

Sanchayita Ghose, Ph.D.

Sanchayita Ghose is currently the Executive Director of Global Downstream Bioprocess Development at Bristol Myers Squibb.  She leads a multi-site team responsible for downstream process development of BMS’ entire clinical biologics portfolio. Sanchayita has > 20 years of experience in bioprocess development with increasing roles of responsibility in a variety of biopharmaceutical companies: BMS (9), Amgen (6), Biogen (5). Over her career, she has made numerous technical contributions in this field and is the author of > 100 conference presentations, publications, book chapters and patents. She has a PhD in Chemical & Biological Engineering from Prof. Steve Cramer’s lab at Rensselaer (Troy, NY) and a BS in Chemical Engineering from Jadavpur University, India. Sanchayita is the mom of two-school aged kids and has lived if four US states across both coasts. In her free time, she enjoys travel, reading and hiking.

Brad Warsen

Brad Warsen is the Executive Director of Quality for the Devens Cell Therapy Facility at Bristol Myers Squibb.  Brad joined Bristol Myers Squibb in 2013 and previously served as the Head of Quality for US Biologics overseeing quality operations at the Devens and Syracuse sites.  Previous to this, he served as the Director of Quality at Devens, interim Director of Quality at Syracuse and as head of Quality Control Operations and Quality Assurance Operations both at Devens.  Brad has over 20 years of quality experience and previously served in quality leadership roles overseeing external manufacturing of biologics drug product at Shire and internal manufacturing of drug substance at Pfizer (including raw materials, compliance and QA Operations roles).  Brad began his career in manufacturing and process development at Pharm-Eco Laboratories and has a BS in Chemistry from Wheaton (IL) College.

Ji Li, Ph.D.

Ji Li is a Principal Scientist at BMS Kendall square site, Mechanism of Cancer Resistance TRC. He currently services as the Biology Lead for two drug discovery projects. He also leads a DepMap data analysis effort and leverages a genome-wide CRISPR screening platform to discover novel cancer targets. Prior to BMS, he worked at the Broad Institute and Dana-Farber Cancer Institute, where he led efforts in functional cancer genomics and the identification of synthetic lethality in breast cancer. Ji received his Ph.D in Cell Biology from NYU School of Medicine and a Bachelors’ degree in Biomedical Sciences from Peking University.

Chun Shao, Ph.D.

Chun Shao is a Principal Scientist at BMS Devens site, who joined Bristol-Myers Squibb in 2018. Chun interfaces closely with biologics process development upstream/downstream team and provides mass spec analytical support for bioprocess optimization. Chun is also co-leading Devens PAN chapter to drive Diversity & Inclusion initiatives. Prior to BMS, Chun worked at GlaxoSmithKline between 2016 and 2018 as characterization lead to support biologics process development. Chun received her PhD degree in Biochemistry from Boston University in 2016.  Chun is a big fan of Boston Celtics and Bruins and looking forward to shouting out loudly in TD garden soon with crowds!

Robert Flaumenhaft, M.D., Ph.D.

Dr. Flaumenhaft is a Professor of Medicine at Harvard Medical School and Chief of the Division of Hemostasis and Thrombosis. His laboratory focuses on endothelial & platelet biology and mechanisms of thrombus formation. Dr. Flaumenhaft is director of the T32 training program, “Blood Coagulation and Vascular Biology” and has editorial positions at Blood, JCI Insight, Thrombosis and Haemostasis, Thrombosis Research, and Seminars in Thrombosis and Hemostasis. He is Chairperson of the Hemostasis, Thrombosis, Blood Cells, and Transfusion NIH Study. He was the scientific co-chair of the ASH 2019 meeting and was the Chairman of the FASEB meeting on Functional Disulfide Bonds in Health and Disease. He has received awards from the Burroughs Wellcome Fund, the American Society of Hematology, and the American Heart Association. He was elected to the American Society for Clinical Investigation and subsequently to the American Association of Physicians. He is the recipient of an Outstanding Investigator Award from NIH.

Ai-Min Hui, MD, Ph.D. President of Global R&D, CMO, and Chair of the Scientific Committee of Fosun Pharma;Director of Shanghai Key Laboratory of Stem Cell Therapy; Former global Vice-President of Clinical Development Oncology at Sanofi

   Dr. Hui has 30 years of experiences in cancer treatment and innovative drug development in world's top medical centers and pharmaceutical companies. He has led the global development and registration of multiple small molecule and biologic anti-cancer drugs including Ixazomib, Isatuximab (anti-CD38) et al. He has recently led the deal of the joint development of an mRNA vaccine against COVID-19 BNT162 between BioNTech and Fosun Pharma and the execution of the program.

Julia Ding, Ph.D.

Julia Ding is leading process analytical development at Bristol Myers Squibb biologic development sites in US. She is leading diverse and cross-functional teams responsible for: Establishing strategic vision and implementation of global biologic PAT and rapid analysis technology development; Establishing and advancing new technologies in PAT and real-time release of biologic process; Developing and implementing analytical methodologies to enable and support bioprocess development and characterization; Advancing analytical CMC control strategies throughout biologic clinical development phases.

Prior to joining Bristol Myers Squibb, Julia Ding led a multifunctional analytical development team responsible for analytical assay development/validation/life cycle management, characterization and cGMP quality control testing of biologic products at PPD. Julia obtained her Ph.D. in physical organic chemistry from Emory University and postdoc from University of California at Berkeley.

Qingcong Lin, Ph.D.

Dr. Qingcong Lin is SVP of Biocytogen and CEO of Biocytogen Boston Corporation, focusing on providing services on gene-targeting and humanized mouse models, using cutting-edge ESC and CRISPR-Cas9 technology for immuno-oncology antibody candidate in vivo efficacy and toxicity assessment. Prior to joining Biocytogen, Dr. Lin was SVP of Shenogen Pharma Group. Dr. Lin has extensive expertise in multiple therapeutic areas, including cancer, CVMD, neurology, immunology & inflammation and various technologies, including genetically engineered mouse models, therapeutic antibody engineering, affinity maturation and optimization. Prior to joining Sheongen, Dr. Lin worked at Pfizer as a principal research scientist II and group leader of antibody engineering group. Before joining Pfizer, he worked at Wyeth and Harvard Medical School as Director of Gene Modification Lab of Harvard-Partners Center for Genetics and Genomics. Dr. Lin received Ph.D. from Albert-Einstein College of Medicine and completed his postdoctoral training at Harvard Medical School.

Ambar Boodhoo
Ambar is Americas Life Sciences Strategy and Transactions Leader at EY. He advises life sciences and health care clients on their capital and transaction agendas from strategy through execution, primarily focusing on large, complex investments. Over the last 20 years, he has supported private equity funds and corporate clients in transformational transactions to realize their strategic objectives and improve growth. His experience includes financial and operational diligence in taking companies private, leveraged recapitalizations, carve-outs, rollups, divestitures, PIPE and public financing. He has worked extensively in the UK and the US, and has led global engagements with clients and transaction teams in Europe, India, the Middle East and Asia.

Alex Li, Ph.D. Managing Director of TF Capital

Board Director of SAPA, previous president of SAPA-NE

Dr. Alex Li is a venture capital investor with investing experience in both United States and China. He specialized in the life science industry with focus on cutting edge technology and first-in-class therapeutic medicine. He currently serves on the boards of five innovated companies. TF Capital, one of the premium venture capital fund in China, have invested in near 100 companies, with successful exits like Zai Lab, Hua Medicine, Henlix, and Frontage, etc. Alex is one of the three investment decision committee members in TF Capital. Before Joining TF Capital, Alex was Managing Director of Fosun Pharma for three years. Alex worked as a research scientist in Biogen for seventeen years. Alex obtained his Ph.D. degree in Biochemistry, Cellular and Molecular Biology (BCMB) from the University of Tennessee.

How to become a SAPA-NE Member?

Paid Membership Rate

Student & Postdoc (Annual): $15

Professionals (Annual): $30

Life-time: $300

Note: Paid membership will be effective immediately after purchase.

2021摩根会议周期间 SAPA与BioNJ联合推出网络研讨会(链接更新)

SAPA-HQ 美中药协SAPA 

2021年J. P. Morgan会议周期间, 美中药协SAPA与BioNJ将联合推出网络研讨会,关注医药领域美中企业间的合作。


2020年十月初在第28届SAPA年会上,SAPA与BioNJ签订了长期合作的协议。此次网络研讨会将是两个组织联手举办的第一个活动。


本次研讨会主题包括


01

美中生物制药行业现状

02

新泽西相关的美中合作机会

03

两国的监管环境与流程

04

投资者对在美中开展业务的见解


时间

1月14日, 2021
8:30-10:30 AM EST

网页介绍:

http://campaign.r20.constantcontact.com/render?preview=true&m=1102061150585&ca=e0e04c4c-ecb1-46d4-a3f8-ff81b39e0968&id=preview


本活动免注册费。注册链接更新,已注册的仍然有效。

注册链接: 

扫描下方二维码注册或点击阅读原文注册



https://myemail.constantcontact.com/Webinar---China-and-U-S--Collaboration--Innovation-on-the-Horizon.html?soid=1102061150585&aid=56d6P4bovQA





Modified on 2021-01-10
2020 SAPA-NE Career Development Webinar

 SAPA-NE 美中药协SAPA 

S

M

T

W

T

F

S


_


_

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31


_


_

2020

DECEMBER

2


活动时间:
2020年12月2日 8:00 PM - 9:00 PM 
(EDT, 美国东部时间)


请点击以下链接或扫描右侧二维码进行注册

https://www.sapa-neweb.org/2020stock_tax



_

美中医药开发协会新英格兰(SAPA-NE)将于2020年12月2日携手安永(EY),邀请行业专家为你详细讲述美国员工股权激励计划以及相关税务影响。


不管你是初入职场,创业达人,或者企业高管,员工股权激励计划都与你息息相关。当下,股权激励已经成为薪酬架构中非常重要的一部分。一方面,公司通过股权激励来吸引和保留人才,另一方面,员工有机会借助税务递延的优势实现财富的积累。然而越来越复杂的股权激励计划是否常常让你困惑?各种形式的股权激励计划到底是什么意思?在注定不平凡的2020年以及后疫情时代,如何更好的在员工股权计划中受益?我们邀请到安永的资深专家为大家剖析不同形式的股权激励计划,以及相关的公司或个人层面的美国税务影响。


_

演讲嘉宾 

Jason S French

Managing Director, People Advisory Services


Jason is a Managing Director in the People Advisory Services practice of EY, with 15 years of experience related to the analysis, design and implementation of compensation and benefit matters for both US domestic and internationally mobile employees. Jason’s areas of expertise are specifically within the compensation and benefits space for both US and multinational companies around the globe, equity compensation, global equity, golden parachutes, annual & long-term incentive plan and design, payroll and tax withholding, and US tax technical matters. Jason also advises companies on SEC Executive Compensation Proxy Disclosure rules and director compensation matters.


Claudia Timmermans

Senior Manager, People Advisory Services


Claudia has over 8 years of experience advising clients regarding (global) compensation and benefits arrangements. Claudia has significant experience on assisting clients with maximizing the benefits of equity compensation plans for mobile employee workforces, which includes advising clients on equity plan design and implementation, tax feasibility and due diligence, risk mitigation, global payroll transformation and employee education. She also advises clients on the implications of Internal Revenue Code Sections 162(m), 280G (golden parachutes), 409A, and 457A. 


点击阅读原文(Read More) 进入注册链接 

Read more
Reads 272

2020 CABA Boston BioForum Online

 Jo Lee CABA 

Boston

BioForum 

On


在疯狂的2020年压抑了太久,CABA Boston BioForum Online将于12月19日举行,为这不平凡的一年做个强势收官,总结COVID-19带来的危与机,预测生物医药投资趋势,并展望美中两个大经济体生物医药业的未来。会议邀请了数位行业大咖与大家齐聚线上,与您分享探讨2020年生物医药大事件!


Topics

热点话题

1

Chuan He, PhD, Professor, HHMI, University of Chicago

RNA Methylation in Human Diseases


Speaker Bio:

Dr. He is the John T. Wilson Distinguished Service Professor in the Department of Chemistry and Department of Biochemistry and Molecular Biology at the University of Chicago. He received his bachelor of science degree in 1994 from the University of Science and Technology of China and his Ph.D. in chemistry from the Massachusetts Institute of Technology in 2000, studying under professor Stephen J. Lippard. After training as a Damon-Runyon postdoctoral fellow with professor Gregory L. Verdine at Harvard University, he joined the University of Chicago as an assistant professor, rising to associate professor in 2008 and full professor in 2010. He was selected as an investigator of the Howard Hughes Medical Institute in 2013. Dr. He’s research spans a broad range of fields including chemical biology, RNA biology, epigenetics, biochemistry, and genomics. His recent research concerns reversible RNA and DNA methylation in biological regulation. In 2011, his group discovered reversible RNA methylation as a new mechanism of gene expression regulation. His laboratory has spearheaded the development of enabling technologies to study the biology of RNA and DNA modifications.

2

Robert DeLuccia, 

Managing Partner and Founder, Acurx Pharmaceuticals

Acurx Developing a New Class of Antibiotics: Preparedness for the Next Infectious Disease Pandemic, Antimicrobial Resistance


Speaker Bio:

Bob DeLuccia has 50 years’ executive and hands-on experience in the pharmaceutical industry involving sales, marketing, manufacturing and new product development with global pharmaceutical companies (Pfizer and Sanofi). Mr. DeLuccia has held senior executive positions in both companies and has also been Chief Executive Officer of two publicly (NASDAQ) traded biopharmaceutical companies (Immunomedics, Inc. and MacroChem CORP). He was most recently Executive Chairman of publicly-traded (NASDAQ) Dipexium Pharmaceuticals, Inc., a development-stage biopharmaceutical company based in New York City which he co-founded and subsequently took public. In April, 2017, Dipexium closed a merger with PLx Pharma Inc. (PLXP-NASDAQ), a late-stage specialty pharmaceutical company focused on developing AspertecTM, its aspirin product in its proprietary PLxGuardTM drug delivery system to provide high-risk cardiovascular and stroke patients with more reliable and predictable antiplatelet efficacy and better tolerated treatment. He is currently Co-Founder and Managing Partner of Acurx Pharmaceuticals, a New York-based, development-stage biopharmaceutical company focused on developing a new class of antibiotics to treat common infections caused by certain Gram- positive bacteria and to combat the global crisis of antimicrobial resistance (AMR) to currently available antibiotics. He is also a member of the Board of Directors of IBEX Pharmaceuticals, a publicly- traded (IBT.V/TSXV.IBT), Montreal-based company involved in the manufacture and marketing of proteins for biomedical use and arthritis assays widely used in osteoarthritis research. 

His therapeutic areas of marketing experience include new product introductions and drug development in the following areas: Antibiotics and antidiabetic agents: (doxycycline, bacampicillin, cefaperazone, chlorpropamide and glypizide); Cardiovasculars: amrinone, iohexol contrast media, clopidogrel. New drug development areas included: topical creams/gels for erectile dysfunction, testosterone, onychomycosis and diabetic foot infection. 

Mr. DeLuccia received his undergraduate degree and MBA from Iona College, New York. Military Service, Officer, U.S. Army Corps of Engineers. 

3

Ricky Sun, PhD, Partner, Bain Capital Life Sciences

Life Science Investing, a Global Perspective



Speaker Bio:


Experience

Dr. Sun joined Bain Capital Life Sciences in 2016 and is a partner. He is currently a member of the Board of Directors of Arcutis (NASDAQ: ARQT), Annexon (NASDAQ: ANNX), and Savara (NASDAQ: SVRA). He is also a board observer of Pharvaris. Previously he also served as a board observer for Replimune (NASDAQ: REPL).

Prior to joining Bain Capital, from 2013 to 2016, he was a Director of Corporate Development and Strategy at Biogen. Prior to Biogen, Dr. Sun served as a Vice President at BlackRock, as a member of the Fundamental Equity division of BlackRock's Alpha Strategies Group and senior analyst for BlackRock's Fundamental Large Cap Growth equity team, covering the health care sector. Prior to that, he was a senior healthcare analyst at Citadel and Alyeska Investment Group in Chicago and worked as a pharmaceuticals equity research analyst on Wall Street, spending time at Lehman Brothers and Morgan Stanley. Dr. Sun began his career as a senior scientist at Ironwood Pharmaceutical where he was involved in the discovery and development of the drug Linzess for irritable bowel syndrome.


Education

Dr. Sun received a PhD degree in Chemistry and Chemical Biology from Harvard University and was an NIH post-doctoral fellow in Biological Chemistry & Molecular Pharmacology at Harvard Medical School.  He also received an MBA from New York University Stern School of Business, where he was a Mildred Elperin Scholar.  He graduated summa cum laude from Berea College with a BA in chemistry.

4

Chris Garbedian, CEO, Xontogeny

Venture Investment in Rare Diseases


Speaker Bio:


Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. In 2017, Chris joined Perceptive Advisors to develop their Venture Fund strategy and launched the Perceptive Xontogeny Venture Fund in 2018 to support early stage companies seeded and incubated at Xontogeny and other ventures.

Chris has a broad base of experience and a track record of success over his decades long experience in the biopharma industry. Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial stage leader in the genetic technology space after leading the development of the company’s Duchenne Muscular Dystrophy program. Prior to Sarepta, Chris led Corporate Strategy for Celgene from 2007 to 2010. Prior to Celgene, Chris served in a number of global commercial and corporate development leadership roles at Gilead from 1997 to 2005.

5

Angus Grant, PhD, Chief Business Executive, BeiGene

Building Portfolio with Business Development Support for China



Speaker Bio:


Angus Grant, Ph.D., joined BeiGene in June 2020 as Chief Business Executive, bringing in more than 25 years of experience across multiple key functions in the biotech industry, including business development, alliance management, research and development, and regulatory affairs . In this role, Dr. Grant will oversee business development and alliance management, and help drive external innovation and investment in other companies to guide BeiGene’s global growth strategy. Prior to joining us, Dr. Grant was the CEO of the Dementia Discovery Fund (DDF), a specialist venture capital fund focused on therapeutics for age-related dementias and neurodegenerative disease. Before that, Dr. Grant spent 12 years at Celgene (now a Bristol Myers Squibb company) serving various executive roles, including Corporate Vice President of Business Development and Vice President, Regulatory Affairs. Earlier in his career, Dr. Grant worked in business development and regulatory roles at Novartis, Merck KGaA, Rhone Poulanc-Rohrer, SmithKline Beecham, and the U.S. Food and Drug Administration’s Center for Biologics. He currently serves as the Chairman of the Board for Toronto Innovation and Acceleration Partners. Dr. Grant received a bachelor’s degree from the University of Richmond and a Ph.D. in Anatomy and Immunology from the Medical College of Virginia, and completed his postdoctoral training at the National Cancer Institute.


日期:2020年12月19日

时间:美东时间早上9点/中国时间晚上10点

Join Zoom Meeting


Meeting ID: 879 9988 3589

Passcode: 498231


按二维码参加会议


CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development.


Chinese-American BioMedical Association


【预告】数字科技下的精准精神健康治疗|医路领航第四期

 哈佛中国健康协会 Harvard Healthcare Club 

本文共1841字,阅读约需6分钟



数字科技下的精准精神健康治疗

医路领航研讨会 第四期

在世界范围内,大约有七分之一的人曾患有精神健康疾病,而且这个比例还在持续增长。除了未满足的医疗需求外,精神健康疾病还会导致社会生产力下降约35%,人均预期寿命缩短10-25年,从而导致巨大的社会和经济负担。一方面,早期筛查和诊断以及进行早期干预治疗可以有效地延迟甚至预防疾病的发作,并最大程度地减少对患者和家庭造成的情感和经济损失。另一方面,从长远角度来看,持续的随访和治疗进展监测对于预防复发和提高患者的生活质量至关重要。但是,与当前护理模式中的疗法相比,预防和随访在很大程度上被忽略了


通过先进的人工智能算法和多模式大数据,数字化精神健康产品现在能够捕获个人的数字化生物标记物,从而在整个连续治疗过程中提供个性化护理,包括提供早期诊断、治疗建议以及进行持续的患者监测。


我们很荣幸地邀请到了两位来自数字化精神健康治疗领域的发展先驱公司的演讲嘉宾,与我们分享他们的公司愿景,以及他们对数字化精神健康治疗未来的看法:Paul Dagum博士(Mindstrong的创始人和前首席执行官),Sharief Taraman博士(Cognoa首席医务官。Cognoa专注于儿童神经发育障碍的治疗,例如自闭症和注意缺陷与多动障碍;Mindstrong关注对严重的精神障碍的治疗。


0

1

Dr. Paul Dagum



Mindstrong是一家医疗创新公司,以Mindstrong的创始人,副董事长兼首席科学官Paul Dagum博士的前瞻性研究作为基础。Mindstrong致力于通过数字化测量,利用数据科学和线上护理模型的创新来改变精神健康状态。

     


Mindstrong提供的解决方案和健康服务有助于在护理过程中抢得先机以改善治疗效果。他们得到了ARCH Venture Partners,General Catalyst,Foresite Capital,Optum Ventures,8VC等投资公司的支持。









 


Paul Dagum博士是Mindstrong的创始人,并在2019年11月前一直担任其首席执行官。他是一位企业家,也是医师和计算机科学家,他曾作为创始人、首席科学官、首席技术官和首席执行官,将产品、技术和商业模式的创新引入医疗健康、网络安全和供应链领域,并受到了多家知名风险投资公司的支持。Dagum博士对动态贝叶斯网络的早期研究已在许多现代应用中使用。他还开发了用于数据科学的大规模可扩展算法,应用于大量世界领先的数据公司,以及通过从移动设备被动捕获的人机交互中,创建了首个脑功能数字化量度技术,两者均获得了专利。同时,Dagum博士也在持续测量技术和人工智能赋能的远程医疗基础上,设计了用于精神健康的数字化护理模式。


Dagum博士在斯坦福大学期间领导了由美国国家科学基金会(NSF)和美国国立卫生研究院(NIH)资助的研究,发表了超过85篇在计算机科学和医学领域的同行评审文章和书籍章节,并获得了超过25项专利。Dagum博士获得了多伦多大学的理论物理学硕士学位和理论计算机科学博士学位,以及斯坦福大学的医学博士学位和外科住院医师培训。


0

2

Dr. Sharief Taraman



Cognoa是一家市场领先的专注于儿科行为健康的公司。Cognoa正在开发处方数字疗法,以更早地识别和治疗行为健康问题,从而改变护理标准,并改善会影响儿童终身的治疗效果。Cognoa的主要处方产品,包括首个针对自闭症的数字诊断技术和首个针对自闭症儿童的处方数字化疗法,均已获得FDA的突破性设备称号。 


该公司的AI技术平台还同时支持Cognoa的其他产品线,包括解决来自ADHD和焦虑症等其他未满足的临床需求。



 


医学博士Sharief Taraman获得了神经病学领域的双重认证,包括美国精神病学委员会的儿童神经病学和美国预防医学委员会的神经病学及临床信息学的专业资格认证。他是CHOC儿童专科学院的儿科神经病学系主任,也是加州大学欧文分校医学院的临床副教授


Taraman博士是儿科行为健康公司Cognoa的首席医务官,该公司的前两个处方数字化设备均获得了FDA突破性设备的称号,这两种设备旨在提高行为健康问题的早期治疗的护理标准。



活动安排


研讨会主题

数字科技下的精准精神健康治疗


主讲嘉宾

Mindstrong - Paul Dagum, MD, PhD

Cognoa - Sharief Taraman, MD


活动方式

Zoom 直播


活动时间

美东时间: 11月21日 8:00-9:00 pm

美西时间: 11月21日 5:00-6:00 pm

北京时间: 11月22日 9:00-10:00 am


报名链接

扫描下方二维码或点击“阅读原文”报名



审核通过后,将由邮件确认参会方式


活动鸣谢

统筹:茅傲岳 朱子溪 闫姿秀 王目阔 

王硕 王紫 戴钰

文字:闫姿秀

美编:王紫 朱霁清

特别感谢:盛开


医路领航研讨会

医路领航研讨会(Frontier Healthcare Cross Talk)以激励创新技术转化为目的,以研讨会为载体,邀请中美的顶级投资人、头部企业、优秀创业公司、及来自哈佛、MIT等的专家学者,帮助哈佛及友校的学生学者群体跟踪最实用的前沿医疗产业动态,协同中美医疗业界掌握最干货的前沿科学研究成果。通过定期跨学科、跨领域的不断探讨,共同助力技术创新上、中、下游的对接与耦合。

往期回顾

医路领航第三期数字疗法重新定义精神健康治疗

医路领航第二期人工智能赋能药物研发

医路领航第一期AI如何助力数字化战疫 

哈佛中国健康协会是哈佛大学首个专注于中国医疗系统系统和健康产业的学生组织,致力于通过对话顶尖世界学者及行业领袖、中国产业参访行和专题研讨会等活动,帮助哈佛学生学者打破学术和产业界的信息壁垒、深入探讨中国医疗健康发展趋势,凝聚专业化的人才网络,启迪未来医疗健康领域的引领者。


有興趣在美國長期發展的朋友看過來囉!

波士頓台灣人生物科技協會 (BTBA) 與哈佛台灣學生會 (HTSA) 將合作舉辦「綠卡&H1B申請線上講座與經驗分享」,邀請綠楓法律集團創所律師陳啟耕律師 (Danny Chen) 主講綠卡及H1B申請的過程,並邀請三位不同身份轉換取得綠卡的學長姊分享自身經驗。本講座將包含以下主題:

- 各種身份 (F, J, OPT)如何銜接轉換綠卡或H1B?
- 何種條件、時機可以開始申請綠卡?要累積什麼經驗、資歷對申請綠卡有幫助?
- EB1、EB2申請難度及條件?
- 學長姊過來人經驗分享,若時光倒流他們會/不會做的事是什麼?
- 近期移民政策對申請綠卡、H1B的影響

歡迎同學們和BTBA的各位,請先填寫與會報名表,也讓我們知道你有什麼問題,我們會先行告知律師和學長姐準備回答你的問題喔!
https://forms.gle/yDByicWFSp73MdUk6

[活動分享] BTBA monthly Seminar!
=========================================
BTBA Monthly seminar is back! We are happy to have two outstanding scientists from the Harvard community to present their recent work.
*Kai-Ting Shade (Instructor, Massachusetts General Hospital)
"Sialylation of immunoglobulin E is a determinant of allergic pathogenicity"
*Annie Cheng (Postdoc, Brigham and Women's Hospital)
"Nanoparticles: A multifunctional vehicle for theranostics"
Moderator: Jerry Lin (Postdoc, Massachusetts General Hospital)
Meeting link coming soon!
SAPANE獎學金9/18報名截止






最近開始有點秋天的氣息,就表示新的年度又要來了!!感謝過去一
路以來大家的支持和鼓勵,就是下週日9/13,
BTBA-Boston Taiwanese Biotechnology Association
要來舉辦2020-2021 Welcoming party!!
走過路過不要錯過~ 派對上我們要一起來討論接下來新活動內容,另外也想聽取大家的意見跟未來活動喜好。相較於過往的學業界活動,新的一年我們還有新面向的互動方式喔~ 希望在這個疫情期間,BTBA的大家可以透過迎新趴認識一下新來到波士頓的朋友,還有一路陪伴的老朋友們!
滑鼠往下按連結就可以報名參加這次的迎新派對了! 希望下週日可以線上見囉! 如果有任何問題歡迎聯絡今年負責人
22021 BTBA VIy
We are excited to invite everyone to come and join 2020-2021 Boston Taiwanese Biotech Association (BTBA) Virtual Welcome Party on September 13, 2020!

Hope everyone is well, healthy, and safe during the pandemic. As the new school year arrived, BTBA welcomes everyone who calls Beantown a new home to join our virtual welcome party on September 13, 2020! No matter you are an academic professional, a biotech professional, a postdoctoral researcher or a student, we sincerely invite you to come and connect with us. At BTBA, you will find a group of passionate scientists and enthusiasts to network and discuss career opportunities & possibilities, healthcare related topics, life science research, pharmaceuticals, drug discovery start-ups as well as the innovation and technology that powers it all.
We thrive because of you!
We are thrilled to get to know you, so come and join us!

各位親愛的朋友,大家好!希望大家在COVID期間都健康平安! 新的學年又要開始囉!波士頓台灣人生物科技協會 (BTBA) 今年的第一場活動將在 9月13日 登場~! 歡迎新朋友&老朋友一起來互相認識,不管是來念書,來工作,來當Postdoc,都不要錯過BTBA的活動。不是生物領域,也沒有問題!來聽聽看新的一年可以有甚麼精彩可期的活動!

時間 / Time:
2020-09-13 (Sun) 1 pm - 3 pm

地點 / Place:
Microsoft Team Meeting
Meeting link will be sent separately, please make sure leave your e-mail below!

聯絡人 / Contact:
Yvonne Meng 孟憲薇; hsienweimeng@gmail.com
Erica Cai 蔡佩珊; ericapscai@gmail.com

Please complete this form to RSVP (Registration is free!).

Follow & Like us on Facebook: https://www.facebook.com/btbatw/

會議流程 / Event:
1:00 am – 1:30 pm Meet and Greet
1:30 pm – 2:00 pm BTBA Introduction
2:00 pm – 3:00 pm Networking


美中藥協年度科學盛會【2020 SAPA科學論壇】將於8月15日(星期六)以網絡會議形式舉行。

今年主題是“生物醫學創新轉型的驅動力”,將重點關註生物醫學創新在🩺診斷與精準醫學,🧬細胞與基因療法,以及藥物研發的新技術等領域的最新趨勢與突破。世界知名的科學家,包括哈佛大學的George Church教授和斯坦福大學的Richard N. Zare教授,以及諸多製藥行業領導者、科學家和企業家,將分享他們對生物醫學創新的思考與見解。 🔛論壇還設有互動交流小組會議,提供了同主講人和資深業內人士在線面對面交流的機會。
SAPA會員福利免費註冊 ,學生註冊享優惠!
⏰時間:2020年8月15日 週六 9:00 AM-5:00 PM EDT
🔗註冊鏈接:https://sapaweb.org/event/2020-scientific-symposium/

2020 BTBA Virtual Symposium in two weeks!!!
This year, we are honored to have Dr. Taiyin Yang, the Executive Vice President of Gilead Sciences, who supervised the development of Remdesivir, to deliver the keynote address.
Please also check out the rest of meeting agenda!
*Flyer designed: Amy Kao

7月11日 OCEAN-BIO SEMINAR:中美投资并购中的国家安全审查和出口管制问题

 OCEAN BIO 海华会生物分会 2 days ago
2020年02月13日,美国财政部于今年年初颁布的全面实施《2018年外国投资风险审查现代化法案》(Foreign Investment Risk Review Modernization Act of 2018)(“FIRRMA”)的两项最终实施条例(“实施条例”)正式生效实施。


FIRRMA及其实施条例正式施行后,有可能给未来的中美投资及并购带来“寒蝉效应”。中美投资并购活动将面临更为复杂的监管环境,必须及时从国家安全审查角度进行有效的评估,并据此提前进行合适的筹划安排。





00100


2020年07月11日,海外华人企业家联合会生物分会(OCEAN-BIO)将邀请著名国际律师事务所Dorsey & Whitney(德汇律师事务所)合伙人、德汇全美及中国联合业务主席——潘惜唇律师,为大家做“中美投资并购中的国家安全审查和出口管制问题”的主题演




直播时间
美东时间 2020年7月11日,周六,晚八点
July 11, 2020, Saturday, 8PM, US Eastern Time
Zoom Link: https://us02web.zoom.us/j/8151859178
Zoom ID: 815 185 9178
Mobile:  +13126266799, 8151859178# US (Chicago)
             +19292056099, 8151859178# US (New York)

----------------------------------------------------------
本次网络直播会议
对全球华人企业家免费开放

SAPA 健康投资论坛暨路演六月线上举行 项目资本双向征集

 SAPA-HQ 美中药协SAPA 3 days ago



2020 SAPA Roadshow
新冠肺炎疫情给全球社会经济带来深刻影响,整个创业生态和风险投资领域面临着极大的冲击。然而“危”中有“机”,医药健康行业逆行而上获得高度关注,疫情同时也激发产业变革,催生新的发展机遇。

2018年以来在大纽约地区名声鹊起, 广受投资人和企业家们喜爱的美中药协(SAPA)旗舰活动 – 2020 SAPA健康产业投资峰会暨项目路演,将因时而变,重新设计为线上和线下两个部分:第一部分为线上部分,包括投资论坛有关投资和创业的主题演讲和讨论,一系列的线上路演,1对1会议。

首轮路演将于2020年6月20日举行。第二部分线下会议将在10月初的SAPA 2020年会上举行。
在这里,您将通过SAPA创投平台:
•  了解最新生物医药的投资和研发最新动态
•  与顶尖的投资人交流互动
•  与天使轮到Pre-IPO的各类投资人和各大药厂的BD高层交流互动,了解投资全周期细节
•  企业家和投资人1对1会面,充分展示/了解项目和交流融资兴趣
•  除了获得投资,还可能有对外授权技术和产品的机会
•  获得SAPA药界资深专家和投资界人士的专业评审和建议
•  与同行交流分享经验心得
•  广结善缘,获得更多潜在的人才与合作伙伴资源
•  全线上活动,无地域限制,低成本参与,会后可观看活动录像
征集路演1对1项目

项目报名要求
生命科学行业,包括但不限于:制药生物技术公司医疗器材诊断与数字化健康公司。
每一份申请都会由SAPA投资论坛组委会认真严格审阅,最为优秀的部分项目会邀请在投资论坛进行线上路演,或与投资人进行线上1对1会面。

请填写下方的Google form或者QQ survey报名:
• Google form:  
https://forms.gle/ks8DLZLj5X7BnXUF9
• QQ survey, (如无法使用Google form):
 https://wj.qq.com/s2/5912374/a9d1
征集投资者

我们将邀请知名生命科学领域投资机构投资人担当路演评委。同时也欢迎对活动感兴趣的投资人以及公司BD联系我们,商务拓展负责人及其他相关人员联系我们参加1:1会议。
请填写下方的Google form或者QQ survey
•   Google form:
  https://forms.gle/hU2xYhNQ2N32m5A36
•   QQ survey, (如无法使用Google form):
  https://wj.qq.com/s2/6153302/f8f3
 
首轮线上创投路演报名截止时间
2020年5月29日,星期五,11:59 pm (EDT)
若有疑问或了解更多详情请联系
roadshow@sapaweb.org
欢迎合作伙伴与赞助商